Research
Current Research – Actively Enrolling
Alexion Pharmaceuticals – ALXN-MG-501
A Long-Term, Observational, Registry of Patients with Generalized Myasthenia Gravis Who Have Received Treatment with Complement C5 Inhibition Therapies
Mitsubishi Tanabe Pharma America – MT-1186-A02
A Phase 3b, Multicenter, Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Oral Edaravone Administered for a Period of 48 Weeks in Subjects with Amyotrophic Lateral Sclerosis (ALS)
Mitsubishi Tanabe Pharma America – REFINE-ALS
Radicava®/(Edaravone) Findings in Biomarkers From ALS
Muscular Dystrophy Association – MDACS1
Neuromuscular Observational Research (MOVR) Data Hub
Sarepta Therapeutics – SRP4658-403
A Long-Term Observational Study Evaluating Sarepta Therapeutics, Inc.’s Exon-Skipping Therapies in Patients with Duchenne Muscular Dystrophy under Conditions of Routine Clinical Practice
Current Research – Enrollment Closed
Alexion Pharmaceuticals – ALXN1210-MG-306
A Phase 3, Randomized, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients with Generalized Myasthenia Gravis
Sarepta Therapeutics – SRP4045-301
A Double-Blind, Placebo-Controlled, Multicenter Study with an Open-Label Extension Study to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients with Duchenne Muscular Dystrophy
Sarepta Therapeutics – SRP4045-302
A Long-Term, Open-Label Extension Study for Patients with Duchenne Muscular Dystrophy Enrolled in Clinical Trials Evaluating Casimersen or Golodirsen
UCB – RA101495-02.302
A Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis
For more information on our current research projects, contact our Clinical Research department at research@lavegasclinic.org.